These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25234340)

  • 1. Emerging drugs for schizophrenia: an update.
    Köster LS; Carbon M; Correll CU
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):511-31. PubMed ID: 25234340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel therapy of schizophrenia in children and adolescents.
    Klein C; Bespalov A
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1531-40. PubMed ID: 24970455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational dopamine antagonists for the treatment of schizophrenia.
    Wang SM; Han C; Lee SJ; Jun TY; Patkar AA; Masand PS; Pae CU
    Expert Opin Investig Drugs; 2017 Jun; 26(6):687-698. PubMed ID: 28443355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential serotonergic agents for the treatment of schizophrenia.
    Garay RP; Bourin M; de Paillette E; Samalin L; Hameg A; Llorca PM
    Expert Opin Investig Drugs; 2016; 25(2):159-70. PubMed ID: 26576669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for schizophrenia.
    Biedermann F; Fleischhacker WW
    Expert Opin Emerg Drugs; 2011 Jun; 16(2):271-82. PubMed ID: 21563991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials.
    Rao NP; Remington G
    Expert Opin Investig Drugs; 2013 Jul; 22(7):881-94. PubMed ID: 23639138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.
    Carbon M; Correll CU
    CNS Spectr; 2014 Dec; 19 Suppl 1():38-52; quiz 35-7, 53. PubMed ID: 25403863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M; Correll CU
    Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic drug action: targets for drug discovery with neurochemical imaging.
    Stone JM; Pilowsky LS
    Expert Rev Neurother; 2006 Jan; 6(1):57-64. PubMed ID: 16466312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.
    Garay RP; Citrome L; Samalin L; Liu CC; Thomsen MS; Correll CU; Hameg A; Llorca PM
    Expert Opin Pharmacother; 2016; 17(7):921-36. PubMed ID: 26831200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schizophrenia treatment. Critical review on the drugs and mechanisms of action of antipsychotics.
    Tajima K; Fernández H; López-Ibor JL; Carrasco JL; Díaz-Marsá M
    Actas Esp Psiquiatr; 2009; 37(6):330-42. PubMed ID: 20066585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
    Millan MJ; Brocco M
    Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Current Treatments for Schizophrenia.
    Maric NP; Jovicic MJ; Mihaljevic M; Miljevic C
    Drug Dev Res; 2016 Nov; 77(7):357-367. PubMed ID: 27633376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments.
    Foussias G; Siddiqui I; Fervaha G; Agid O; Remington G
    J Psychopharmacol; 2015 Feb; 29(2):116-26. PubMed ID: 25516370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia: treatment targets beyond monoamine systems.
    Ibrahim HM; Tamminga CA
    Annu Rev Pharmacol Toxicol; 2011; 51():189-209. PubMed ID: 20868275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of dopamine D(2) receptors for antipsychotic activity.
    Ginovart N; Kapur S
    Handb Exp Pharmacol; 2012; (212):27-52. PubMed ID: 23129327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials.
    Rao NP; Remington G
    Expert Opin Pharmacother; 2014 Feb; 15(3):373-83. PubMed ID: 24354659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.